A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection
Completed · Not applicable
Conditions studied: HIV Infections
In brief
To assess the magnitude and duration of the antiviral activity in plasma and the incidence and time to total suppression of detectable HIV RNA in plasma. To assess the long-term safety and tolerability of this combination therapy and the magnitude and duration of the effect of these drugs over CD4 cell counts.
Key facts
- Study ID
- NCT00002177
- Run by
- Bristol-Myers Squibb
- Starts
- 1997-05-01
- Expected to finish
- 2000-03-01
- Last updated by the study team
- 2011-04-14
Who can join
Age: 16 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients must have the following symptoms and conditions:
- Treatment naive.
- Recent HIV infection.
- Baseline laboratory values within acceptable ranges.
- Written, informed consent from parent or legal guardian for patients < 18 years old.
- Available for follow-up for at least 96 weeks.
You may not qualify if…
- Co-existing Condition:
- Patients with the following conditions and symptoms are excluded:
- Documentation of other cause for previously mentioned clinical conditions.
- Intractable diarrhea.
- Signs and symptoms of bilateral peripheral neuropathy >= Grade 2.
- Inability to tolerate oral medication.
- Hemophilia, other bleeding disorder, or no accessible tonsillar or lymph node tissue.
- Patients with the following prior conditions are excluded:
- History of acute or chronic pancreatitis. 1. Use of potent neurotoxic drugs is not permitted.
- No other anti-HIV therapy allowed.
- Nelfinavir should not be administered concurrently with rifampin or rifabutin, terfenadine (Seldane), astemizole (Hismanal), cisapride (Propulsid), triazolam (Halcion), and midazolam (Versed).
- Any prior antiretroviral therapy.
- Prior vaccination with a candidate HIV therapeutic vaccine.
- Previous therapy with agents with significant systemic myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of study start or the expected need for such therapy at the time of enrollment.
- Previous therapy with rifampin or rifabutin, terfenadine (Seldane), astemizole (Hismanal), cisapride (Propulsid), triazolam (Halcion), and midazolam (Versed) within 14 days prior to study entry or at any time while on study.
- Active alcohol or substance abuse.
Where it is running
- Univ of California at San Francisco Gen Hosp — San Francisco, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.